Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Dutch STRIDER
NCT02277132Phase 3Terminated
- Sponsor
- University of Amsterdam
- Start
- Jan 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ASP-001 in fetal growth restriction (FGR) (2 arms), sponsored by University of Amsterdam. Primary endpoint: Intact neonatal survival until term age. Started Jan 2015; status: terminated.
02
Drugs
ASP-001
03
Conditions
fetal growth restriction (FGR)
Beyond the preview
Go deeper on NCT02277132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277132.